SCHEMBL364951

SCHEMBL364951

O=C(O)c1ccc(F)c(Cl)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
CASP1 P29466 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAP2K1 Q02750 2/20 0.42
TP53 P04637 1/20 0.42
GRIK1 P39086 2/20 0.41
ALB P02768 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ADRA2A P08913 1/20 0.41
CLCN2 P51788 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29488311 1.00 TSHR (0.47) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL109128 0.84 TSHR (0.48) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL1774412 0.83 ALDH1A1 (0.48) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL9693756 0.83 CES2 (0.45) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL4847445 0.83 TSHR (0.52) TSHRCASP1SMN1; SMN2KEAP1NFE2L2
SCHEMBL2579411 0.83 CES2 (0.50) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL31392754 0.83 CES2 (0.50) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL15878727 0.81 ALB (0.53) TSHRCASP1SMN1; SMN2KEAP1NFE2L2
Hydrochloric Acid SCHEMBL9860906 0.81 CES2 (0.48) TSHRCASP1SMN1; SMN2CES2CES1
SCHEMBL5802725 0.81 DGAT1 (0.46) CASP1CES2CES1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107286350-A Rare earth coordination polymer with high thermal stability and preparation method thereof 江西师范大学 2017-10-24 CN claimed
CN-105440064-A Rare earth complex and preparation method thereof UNIV JIANGXI NORMAL 2016-03-30 CN claimed
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 US disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 US disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 US disclosed
US-12171739-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC. (US) 2024-12-24 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20240027902-A1 CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-01-25 US disclosed
US-20230359119-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-09 US disclosed
WO-2023211256-A1 NOVEL PIM KINASE INHIBITORS AND USES THEREOF 제일약품주식회사 2023-11-02 WO disclosed
US-20230305394-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-6329391-B1 ANTIBIOTICS, BACTERICIDES USING QUINOLONES THE PROCTER & GAMBLE CO. 2001-12-11 US disclosed
EP-1045823-A1 PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2000-10-25 EP disclosed
EP-1015445-A1 ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 2000-07-05 EP disclosed
US-5945382-A AND A METHOD OF THEIR PREPARATION BY CHLORINATION OF AN INTERMEDIATE ARYLPYRAZOLE; PROTECTION AGAINST FUNGAL DISEASES IN TOMATO, RICE, AND WHEAT PLANTS RHONE-POULENC AGROCHIMIE (FR) 1999-08-31 US disclosed
WO-1999035117-A1 PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1999-07-15 WO disclosed
WO-1999014214-A1 ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES THE PROCTER & GAMBLE COMPANY (US) 1999-03-25 WO disclosed
CN-1152853-A Fungicidal compositions based on 3-phenylpyrazole derivatives for treating plant propagation material, novel 3-phenylpyrazole derivatives and their fungicidal use RHONE POULENC AGROCHIMIE (FR) 1997-06-25 CN disclosed
US-5457104-A Antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1995-10-10 US disclosed
EP-0607825-A1 6-H-4-OXO-3-quinoline-carboxylic acids and their analogues as antibacterial agents BAYER AG (DE) 1994-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 TSHR 4612/4885CASP1 3282/4885SMN1; SMN2 1883/4885
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 TSHR 3599/4885CASP1 4076/4885SMN1; SMN2 2815/4885
US-12171739-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ERBB4, ERBB2, ERBB3 TSHR 565/4885CASP1 4035/4885SMN1; SMN2 4403/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TSHR 2289/4885CASP1 484/4885SMN1; SMN2 4377/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 TSHR 3599/4885CASP1 4076/4885SMN1; SMN2 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.